US 12,064,422 B2
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Michael D. Kaufman, Waltham, MA (US); Scott Bone, Bend, OR (US); Corey Bloom, Bend, OR (US); and Fred Jordan, Bend, OR (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Nov. 22, 2023, as Appl. No. 18/518,093.
Application 18/518,093 is a continuation of application No. 18/448,312, filed on Aug. 11, 2023, granted, now 11,903,933.
Application 18/448,312 is a continuation of application No. 18/178,789, filed on Mar. 6, 2023, granted, now 11,793,795, issued on Oct. 24, 2023.
Application 18/178,789 is a continuation of application No. 18/148,766, filed on Dec. 30, 2022, granted, now 11,896,585.
Application 18/148,766 is a continuation of application No. 17/735,820, filed on May 3, 2022, granted, now 11,612,591, issued on Mar. 28, 2023.
Application 17/735,820 is a continuation of application No. 17/180,241, filed on Feb. 19, 2021, granted, now 11,395,818, issued on Jul. 26, 2022.
Application 17/180,241 is a continuation of application No. PCT/US2020/067560, filed on Dec. 30, 2020.
Claims priority of provisional application 62/968,724, filed on Jan. 31, 2020.
Claims priority of provisional application 62/968,695, filed on Jan. 31, 2020.
Claims priority of provisional application 62/955,062, filed on Dec. 30, 2019.
Claims priority of provisional application 62/955,073, filed on Dec. 30, 2019.
Prior Publication US 2024/0091206 A1, Mar. 21, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 9/0053 (2013.01); A61K 9/10 (2013.01); A61K 47/38 (2013.01)] 20 Claims
 
1. A method of treating gastrointestinal stromal tumors in a patient in need thereof, comprising administering to the patient, once daily, one or more pharmaceutically acceptable tablets for orally delivering a compound represented by Formula (I):

OG Complex Work Unit Chemistry
wherein each pharmaceutically acceptable tablet comprises:
a solid dispersion comprising:
(a) 50 mg of the compound wherein the compound is present in amorphous form; and
(b) hydroxypropyl methyl cellulose acetate succinate; and
aniline in an amount equal to or less than about 5% by weight based on the total weight of the pharmaceutically acceptable tablet.